- Home
- AURA vs SIGA Comparison
AURA vs SIGA Comparison
Compare AURA & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AURA
- SIGA
- Stock Information
- Founded
- AURA 2007
- SIGA 1995
- Country
- AURA United States
- SIGA United States
- Employees
- AURA N/A
- SIGA N/A
- Industry
- AURA Biotechnology: Pharmaceutical Preparations
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- AURA Health Care
- SIGA Health Care
- Exchange
- AURA Nasdaq
- SIGA Nasdaq
- Market Cap
- AURA 396.8M
- SIGA 422.9M
- IPO Year
- AURA 2021
- SIGA 1997
- Fundamental
- Price
- AURA $6.49
- SIGA $6.77
- Analyst Decision
- AURA Strong Buy
- SIGA
- Analyst Count
- AURA 6
- SIGA 0
- Target Price
- AURA $22.33
- SIGA N/A
- AVG Volume (30 Days)
- AURA 217.8K
- SIGA 382.0K
- Earning Date
- AURA 08-07-2025
- SIGA 07-31-2025
- Dividend Yield
- AURA N/A
- SIGA 8.70%
- EPS Growth
- AURA N/A
- SIGA N/A
- EPS
- AURA N/A
- SIGA 0.67
- Revenue
- AURA N/A
- SIGA $120,330,310.00
- Revenue This Year
- AURA N/A
- SIGA N/A
- Revenue Next Year
- AURA N/A
- SIGA $95.31
- P/E Ratio
- AURA N/A
- SIGA $10.28
- Revenue Growth
- AURA N/A
- SIGA N/A
- 52 Week Low
- AURA $4.35
- SIGA $4.95
- 52 Week High
- AURA $12.38
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- AURA 59.68
- SIGA 61.28
- Support Level
- AURA $5.96
- SIGA $6.34
- Resistance Level
- AURA $6.68
- SIGA $7.07
- Average True Range (ATR)
- AURA 0.36
- SIGA 0.22
- MACD
- AURA 0.01
- SIGA 0.02
- Stochastic Oscillator
- AURA 97.70
- SIGA 71.70
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.